Delivery Order SPE2DR25D1104-SPE2DR26FL110
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,013.90 to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100s capsules on January 28, 2026, with an ultimate completion date of January 29, 2026. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. The contractor will perform this delivery from its facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100s capsules valued at $2,554.80, with an ultimate completion date of December 23, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement with the agency. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $19,641.44 to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100-strength capsules on January 7, 2026, with completion scheduled for January 8, 2026. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The order fulfills medical supply needs for federal healthcare systems, including military treatment facilities...
- The Defense Logistics Agency awarded a delivery order valued at $4,292.79 to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100s capsules on January 2, 2026, with an ultimate completion date of January 5, 2026. This competitively awarded, firm fixed-price delivery order represents a routine pharmaceutical procurement with no set-aside designation. The product will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,982.70 to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100s capsules, a pancreatic enzyme replacement therapy. This non-set-aside, competitively awarded contract reflects a firm fixed price arrangement with an ultimate completion date of December 17, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location and serve as the prime contractor for this...
- The Defense Logistics Agency awarded a delivery order valued at $15,277.83 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancrelipase) in 100-count packages. This is a firm fixed-price, non-set-aside contract with a completion date of January 16, 2026, issued on January 15, 2026. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $6,261.24 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancrelipase) in 100-count bottles on January 28, 2026, with an ultimate completion date of January 29, 2026. This is a firm fixed-price, non-set-aside award with performance location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., serves as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $14,780.36 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon DR 100s on January 29, 2026, with an ultimate completion date of January 30, 2026. This non-competitive delivery order represents a firm fixed-price transaction with performance based in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., is a major pharmaceutical distributor serving as a critical vendor for federal...
- The Defense Logistics Agency awarded a delivery order valued at $11,226.15 to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100s capsules on January 28, 2026, with completion targeted for January 29, 2026. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be performed at the contractor's Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on January 29, 2026, for 36,000 unit capsules of Creon DR 100s, with a ceiling value of $1,641.42 and an ultimate completion date of January 30, 2026. This is a firm fixed-price delivery order executed without set-aside designation, reflecting open and competitive procurement. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company serves as a...
- SPE2DR25D1104Indefinite Delivery Contract
- SPE2DR25D1104-SPE2DR26FL110Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $25,575.69 to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100s capsules on February 3, 2026, with an ultimate completion date of February 4, 2026. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a subsidiary of Cencora, Inc., a major pharmaceutical distributor serving federal healthcare systems including military treatment facilities and veterans' programs. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with the Defense Logistics Agency Troop Support Medical, valued at up to $999,999,999.00 through December 2026. The prime contract serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and related medical commodities. The Defense Logistics Agency plans to transition to a Pharmaceutical Prime Vendor Global Program Generation V structure with multiple regional awards, underscoring the strategic importance of reliable pharmaceutical distribution to federal healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $25.6k | 2/2/26 |